Xencor Inc. (XNCR) Thursday announced that it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bipecific T-cell engager.
Xencor has advanced the targeted compound through Phase 1 clinical development in hematologic cancers, as per the collaboration and license agreement with Janssen Biotech, Inc. in 2021. The Phase 1 enrollment was completed in late 2023.
Janssen has retained its rights to develop and commercialize B-cell targeting CD28 bispecific antibodies, including JNJ-940 and JNJ-1493.
Xencor said it is eligible to receive additional development, regulatory and sales-based milestone payments, and tiered royalties on approved products in the high-single to low-double digit percent range of net sales.
Plamotamab is an investigational XmAb bispecific antibody that contains both a CD20 binding domain and a cytotoxic T-cell binding domain.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.